SUBSCRIBE
SUBSCRIBE

PsychoGenics Inc.

NEWS
Studies on longer treatment periods with Paxlovid
Pharm Country
Top 10 Pharm Country Companies to Receive NIH Funding in 2020
Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.
March 3, 2021
 · 
6 min read
 · 
Alex Keown
Drug Development
Coeptis Pharma Buys Elto Pharma for Phase II Parkinson’s Asset
Elto Pharma is developing eltoprazine, which is in Phase IIb clinical development for Parkinson’s disease levodopa-induced dyskinesias, or Parkinson’s LID.
November 28, 2018
 · 
3 min read
 · 
Mark Terry
Deal Spree Continues as Allergan Inks $2.47 Billion Deal for This Bay Area Biotech
Job Trends
Allergan to Consolidate Four New Jersey Locations Into One New U.S. HQ in Madison; PsychoGenics Also Moving In
August 9, 2016
 · 
2 min read
JOBS
IN THE PRESS
Press Releases
PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain
October 8, 2024
 · 
2 min read
Pharm Country
PsychoGenics Launches an Updated Corporate Identity and Brand
November 10, 2023
 · 
2 min read
Pharm Country
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders
September 5, 2023
 · 
4 min read
Business
IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
July 25, 2022
 · 
3 min read
Pharm Country
PsychoGenics’ High Data Security Standards Are Certified by The NIH
January 12, 2022
 · 
2 min read
Business
PsychoGenics Appoints Mark A. Varney, Ph.D. as Chief Scientific Officer
November 4, 2019
 · 
3 min read
Business
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia
September 27, 2019
 · 
8 min read
Genetown
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
May 10, 2019
 · 
7 min read
Drug Development
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia
December 13, 2018
 · 
10 min read
Business
PsychoGenics Achieves A Milestone In Drug Discovery Collaboration With Sunovion
June 13, 2017
 · 
2 min read
Load More